t cell vegf other surface atezolizumab antigenrvegf- r rtk-r · dna-pk m3814 parp olaparib...

1

Ras Raf MEK Btk Src Abl Bcr PI3K Akt BAD BCL2 XIAP mTOR Apoptosis RNR p53 MDM2 Survival / Proliferation Angiogenesis Migration / Invasion Mitosis Immunomodulation DNA Replication or Repair Protein expression or metabolism VEGF-R VEGF Other Surface Antigen-R T cell RNR WEE1 PD1 nivolumab pembrolizumab PD-L1 durvalumab atezolizumab IMiDs lenalidomide pomalidomide CTLA4 ipilimumab tremelimumab BiTE blinatumomab CCR4 mogamulizumab CD27 varlilumab IDO-1 epacadostat Dendritic Cell R CDX-1401 IL-12 Cell R IL-12 IL-15 Cell R rIL-15 Oncolytic talimogene laherparepvec BER methoxyamine ATR M6620 AZD6738 DNA-PK M3814 PARP olaparib talazoparib veliparib HDAC belinostat entinostat romidepsin DNA polymerase IPdR EZH2 tazemetostat triapine gemcitabine DNA methylation azacitidine guadecitabine HER2 trastuzumab IGF-1R ganitumab CD30 brentuximab GPNMB glembatumumab Mesothelin anetumab ravtansine radiopharmaceutical radium-223 thorium-227 Proteosome bortezomib ixazomib adavosertib KRT232 triapine gemcitabine Glutaminase-1 telaglenastat HSP-90 onalespib GD2 dinutuximab HGF/SF rilotumumab FGFR rogaratinib UAE TAK-243 E-selectin uproleselan Hedgehog vismodegib Estrogen R endoxifen VEGF-R bevacizumab ziv-aflibercept CD-105 TRC-105 WEE1 adavosertib Aurora kinase A alisertib Microtubules eribulin navitoclax venetoclax temsirolimus RTK-R cMET AMG-337 savolitinib cabozantinib tivantinib PDGFR pazopanib cedirinib sunitinib dabrafenib sorafenib dasatinib copanlisib AZD-8186 ibrutinib selumetinib trametinib TORC sapanisertib cedirinib sunitinib sorafenib cabozantinib birinapant BET proteins i-BET-762 ICOS MEDI-570 Nedd8 AE pevonedistat osimertinib rociletinib DOT1L pinometostat

Upload: ngotu

Post on 11-Apr-2019

213 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: T cell VEGF Other Surface atezolizumab AntigenRVEGF- R RTK-R · DNA-PK M3814 PARP olaparib talazoparib veliparib HDAC belinostat entinostat ... TAK-243 E-selectin uproleselan Hedgehog

RasRaf

MEK Btk

SrcAblBcr

PI3K

Akt

BAD

BCL2

XIAP

mTOR

Apoptosis

RNRp53MDM2

Survival / Proliferation

AngiogenesisMigration / InvasionMitosisImmunomodulation

DNA Replicationor Repair

Protein expressionor metabolism

VEGF-R

VEGFOther SurfaceAntigen-R

T cell

RNRWEE1

PD1nivolumabpembrolizumab

PD-L1durvalumabatezolizumab

IMiDslenalidomidepomalidomide

CTLA4ipilimumabtremelimumab

BiTEblinatumomab

CCR4mogamulizumab

CD27varlilumab

IDO-1epacadostat

Dendritic Cell RCDX-1401

IL-12 Cell RIL-12

IL-15 Cell RrIL-15

Oncolytictalimogene laherparepvec

BERmethoxyamine

ATRM6620AZD6738

DNA-PKM3814

PARPolaparibtalazoparibveliparib

HDACbelinostatentinostatromidepsin

DNA polymeraseIPdR

EZH2tazemetostat

triapinegemcitabine

DNA methylationazacitidineguadecitabine

HER2trastuzumab

IGF-1Rganitumab

CD30brentuximab

GPNMBglembatumumab

Mesothelinanetumab ravtansine

radiopharmaceuticalradium-223thorium-227

Proteosomebortezomibixazomib

adavosertib KRT232 triapinegemcitabine

Glutaminase-1telaglenastat

HSP-90onalespib

GD2dinutuximab

HGF/SFrilotumumab

FGFRrogaratinib

UAETAK-243

E-selectinuproleselan

Hedgehogvismodegib

Estrogen Rendoxifen

VEGF-Rbevacizumabziv-aflibercept

CD-105TRC-105

WEE1adavosertib

Aurora kinase Aalisertib

Microtubuleseribulin

navitoclaxvenetoclax

temsirolimus

RTK-R

cMETAMG-337savolitinibcabozantinibtivantinib

PDGFRpazopanibcedirinibsunitinib

dabrafenibsorafenib

dasatinib

copanlisibAZD-8186

ibrutinibselumetinibtrametinib

TORCsapanisertib

cedirinibsunitinibsorafenibcabozantinib

birinapant

BET proteinsi-BET-762

ICOSMEDI-570

Nedd8 AEpevonedistat

osimertinibrociletinib

DOT1Lpinometostat

A Phase II Trial of Pembrolizumaband Entinostat in

A Phase I study of veliparib (ABT-888) in combination with ... · therapy. DLTs were defined as any grade 4 toxicity; any grade 3 toxicity with the exception of nausea, vomiting or

New Phase I Pharmacokinetic Study of Belinostat for Solid Tumors … · 2011. 1. 28. · On Day -7 (Cycle 1 only), all patients will receive a single dose of 400 mg/m2 belinostat

O19 ENCORE-601: Phase 1b/2 Study of Entinostat (ENT) in ......Presented at the Society for the Immunotherapy of Cancer (SITC) Annual Meeting; November 8–12, 2017; National Harbor,

The PARP Inhibitors, Veliparib and Olaparib, Are Effective ... · reverse-phase high-pressure liquid chromatography (Waters 2695 HPLC) and analyzed by mass spectrometry (Waters single

Entinostat Neutralizes Myeloid-Derived Suppressor Cells ...Inc.),suspendedinDPBS(Corning)as200mLcontaining5 105 cells,andinjecteds.c.intothemice.Aftertumorswereestablished, the mice

Ongoing Phase III Ro-CHOP Trial of CHOP versus Romidepsin ......1. Belinostat: the BELIEf Phase II trial The big T-cell story out of ASCO was this report of significant single-agent

ENCORE-601: Phase 1b/2 study of entinostat (ENT)€¦ · • Roswell Park • Sarah Cannon Research Institute • Mayo Clinic (Florida) • Medical Oncology Associates (Spokane, WA)

Efficacy/safety of entinostat (ENT) and pembrolizumab ...€¦ · Efficacy/safety of entinostat (ENT) and pembrolizumab (PEMBRO) in NSCLC patients previously treated with anti -PD-(L)1

Veliparib Freebase MS Analysis MedKoo Biosciences …€¦ · : ABT-888. lcd: Test-02. lcm. Chromatogram min mV 0 5 10 15 20 25 0 500 1Det. A Ch1 210nm 4.797 5.416 5.804 6.091 6.630

Results of the Pivotal BELIEF Phase II Trial of Single ... · PDF filePTCL (mostly PTCL NOS, angioimmunoblastic TCL ... Belinostat in relapsed or refractory Peripheral t-Cell Lymphoma

FORCE2016PancreaticCancerSession 84797 · Cisplatin +/- Veliparib in patients With Pancreas Adenocarcinoma and a known BRCA/ PALB2 Mutation NCT01489865: A Phase I/II Study of ABT-888

Projektgruppe Mammakarzinom 27.4 · CDK 4 und mTOR Signalwege ... Phase 2 Studie 290 MBC Patientinnen BRCA 1 / 2+ Präsentation SABCS 2016: Veliparib+Carboplatin+Paclitaxel

DCTD Division of Cancer Treatment and Diagnosis Pharmacodynamic Response in Phase I Combination Study of Veliparib (ABT-888) and Topotecan in Adults with

SHAREHOLDERS LETTER – DEEMER 2015 · 2015 (see below), pave the way for a phase 3 pivotal trial to position belinostat and HOP as 1st-line treatment in PT L2. The phase 3 trial

Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer · workshowedthatlow-dose5-aza,combinedwiththehistone deacetylase inhibitor (HDACi) entinostat, provided

Belinostat in˜combination with˜standard cyclophosphamide,x

Creation of Onxeo skilled international Board of Directors BioAlliance Pharma, a ... First line treatment in PTCL: Beleodaq® + CHOP versus CHOP On going: Phase I combination Belinostat

206256Orig1s000 - Food and Drug Administration · 206256Orig1s000 SUMMARY REVIEW . DD Summary Review NDA 206256 Belinostat 2 ... PTCL randomized to treatment with CHOP …